Article
Dose-escalation and dose-expansion trial evaluating potential of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) initiated and expected to enroll up to approximately 80 patients NGM831 is the second of three programs comprising NGM Bio’s wholly-owned myeloid reprogramming and checkpoint inhibition portfolio to enter the clinic NGM831, NGM707…
Read More
– Preliminary data are expected in the second half of 2022 Excerpt from the Press Release: SAN DIEGO, March 24, 2022 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced the initiation of studies evaluating a library of oligonucleotides designed to…
Read More
Transfer of Trial Sponsorship Final Major Milestone before Initiation of Lung Failure Pivotal Clinical Trial Excerpt from the Press Release: CEANSIDE, Calif.–(BUSINESS WIRE)–Therapeutic Solutions International announced today the execution of a purchase agreement covering sponsorship and leadership of the FDA cleared Phase III pivotal trial assessing JadiCell adult stem cells for treatment of COVID-19 associated…
Read More
Excerpt from the Press Release: BOSTON, March 23, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, in collaboration with teams from, Massachusetts General Hospital, Michigan State University and Northeastern University, published an article in the journal Cancers titled, Clinical Applications of Short Non-Coding RNA-Based Therapies in the…
Read More
Results Demonstrated Anti-BCMA CAR T Cells Derived from Healthy Donors Had Better Immune Fitness and Killing Activity Phase 1 AlloCAR T™ Trials Underway Evaluating ALLO-715 and ALLO-605 for the Treatment of Relapsed/Refractory Multiple Myeloma BCMA Program Clinical Update Expected by the End of 2022 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 23,…
Read More
Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Kirilys Therapeutics, Inc., a private, preclinical-stage biopharmaceutical company founded by investment firm Catalys Pacific, announced today that the Company completed a seed financing led by Lightspeed Venture Partners. The company licensed its lead compound, KRLS-017, from Ube Industries, Ltd., a premier Japanese chemical manufacturer. The company also completed…
Read More
Senior leaders in science, government, and industry recruited for international “Manhattan Project for the Brain” Excerpt from the Press Release: DUBAI, United Arab Emirates & PALO ALTO, Calif. & MONTREAL–(BUSINESS WIRE)–Neurotechnology Powerhouse NeuroVigil (ranked “Top 10 most innovative companies in health care” by Washington Post and Fast Company) announced at the New Technology & Mental…
Read More
Excerpt from the Press Release: SAN JOSE, Calif.–(BUSINESS WIRE)–Broncus Medical (02216HK), Inc., developer of diagnostic and therapeutic technology for a variety of lung diseases, today announced online publication in the Respirology journal of a global, multicenter study demonstrating the effectiveness of the company’s Archimedes® Virtual Bronchoscopic Navigation (VBN) System in guiding the sampling of peripheral…
Read More
CHMP recommendation follows September 2021 U.S. FDA approval of CABOMETYX in this setting – Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX® (cabozantinib) as…
Read More
Novel trial design will compare safety and effectiveness outcomes for the OMNI Surgical System and the iStent inject® in lowering intraocular pressure (IOP) as a standalone treatment option without concomitant cataract surgery. Excerpt from the Press Release: MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative…
Read More